BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

504 related articles for article (PubMed ID: 27390303)

  • 1. Fukuoka criteria accurately predict risk for adverse outcomes during follow-up of pancreatic cysts presumed to be intraductal papillary mucinous neoplasms.
    Mukewar S; de Pretis N; Aryal-Khanal A; Ahmed N; Sah R; Enders F; Larson JJ; Levy MJ; Takahashi N; Topazian M; Pearson R; Vege SS; Chari ST
    Gut; 2017 Oct; 66(10):1811-1817. PubMed ID: 27390303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. "Trivial" Cysts Redefine the Risk of Cancer in Presumed Branch-Duct Intraductal Papillary Mucinous Neoplasms of the Pancreas: A Potential Target for Follow-Up Discontinuation?
    Marchegiani G; Andrianello S; Pollini T; Caravati A; Biancotto M; Secchettin E; Bonamini D; Malleo G; Bassi C; Salvia R
    Am J Gastroenterol; 2019 Oct; 114(10):1678-1684. PubMed ID: 31449158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term Risk of Pancreatic Malignancy in Patients With Branch Duct Intraductal Papillary Mucinous Neoplasm in a Referral Center.
    Pergolini I; Sahora K; Ferrone CR; Morales-Oyarvide V; Wolpin BM; Mucci LA; Brugge WR; Mino-Kenudson M; Patino M; Sahani DV; Warshaw AL; Lillemoe KD; Fernández-Del Castillo C
    Gastroenterology; 2017 Nov; 153(5):1284-1294.e1. PubMed ID: 28739282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progression of Pancreatic Branch Duct Intraductal Papillary Mucinous Neoplasm Associates With Cyst Size.
    Han Y; Lee H; Kang JS; Kim JR; Kim HS; Lee JM; Lee KB; Kwon W; Kim SW; Jang JY
    Gastroenterology; 2018 Feb; 154(3):576-584. PubMed ID: 29074452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-Term Outcomes and Risk of Pancreatic Cancer in Intraductal Papillary Mucinous Neoplasms.
    de la Fuente J; Chatterjee A; Lui J; Nehra AK; Bell MG; Lennon RJ; Kassmeyer BA; Graham RP; Nagayama H; Schulte PJ; Doering KA; Delgado AM; Vege SS; Chari ST; Takahashi N; Majumder S
    JAMA Netw Open; 2023 Oct; 6(10):e2337799. PubMed ID: 37847503
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cross Validation of the Monoclonal Antibody Das-1 in Identification of High-Risk Mucinous Pancreatic Cystic Lesions.
    Das KK; Geng X; Brown JW; Morales-Oyarvide V; Huynh T; Pergolini I; Pitman MB; Ferrone C; Al Efishat M; Haviland D; Thompson E; Wolfgang C; Lennon AM; Allen P; Lillemoe KD; Fields RC; Hawkins WG; Liu J; Castillo CF; Das KM; Mino-Kenudson M
    Gastroenterology; 2019 Sep; 157(3):720-730.e2. PubMed ID: 31175863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of the clinical utility of 4 guidelines in the initial triage of mucinous cystic lesions of the pancreas based on cross-sectional imaging: Experience with 188 surgically-treated patients.
    Park RHS; Lim GRS; Wu JJY; Koh YX; Teo JY; Cheow PC; Chan CY; Ooi LLPJ; Chung AYF; Goh BKP
    Eur J Surg Oncol; 2020 Nov; 46(11):2114-2121. PubMed ID: 32828582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid Growth Rates of Suspected Pancreatic Cyst Branch Duct Intraductal Papillary Mucinous Neoplasms Predict Malignancy.
    Kwong WT; Lawson RD; Hunt G; Fehmi SM; Proudfoot JA; Xu R; Giap A; Tang RS; Gonzalez I; Krinsky ML; Savides TJ
    Dig Dis Sci; 2015 Sep; 60(9):2800-6. PubMed ID: 25924899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of branch-duct intraductal papillary mucinous neoplasms: a large single-center study to assess predictors of malignancy and long-term outcomes.
    Ridtitid W; DeWitt JM; Schmidt CM; Roch A; Stuart JS; Sherman S; Al-Haddad MA
    Gastrointest Endosc; 2016 Sep; 84(3):436-45. PubMed ID: 26905937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low progression of intraductal papillary mucinous neoplasms with worrisome features and high-risk stigmata undergoing non-operative management: a mid-term follow-up analysis.
    Crippa S; Bassi C; Salvia R; Malleo G; Marchegiani G; Rebours V; Levy P; Partelli S; Suleiman SL; Banks PA; Ahmed N; Chari ST; Fernández-Del Castillo C; Falconi M
    Gut; 2017 Mar; 66(3):495-506. PubMed ID: 26743012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Surveillance and Timeline of Progression of Presumed Low-Risk Intraductal Papillary Mucinous Neoplasms.
    Kayal M; Luk L; Hecht EM; Do C; Schrope BA; Chabot JA; Gonda TA
    AJR Am J Roentgenol; 2017 Aug; 209(2):320-326. PubMed ID: 28590817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sendai and Fukuoka Consensus Guidelines Identify Advanced Neoplasia in Patients With Suspected Mucinous Cystic Neoplasms of the Pancreas.
    Kaimakliotis P; Riff B; Pourmand K; Chandrasekhara V; Furth EE; Siegelman ES; Drebin J; Vollmer CM; Kochman ML; Ginsberg GG; Ahmad NA
    Clin Gastroenterol Hepatol; 2015 Oct; 13(10):1808-15. PubMed ID: 25818077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term follow-up of branch-duct intraductal papillary mucinous neoplasms with No change in first 5 Years of diagnosis.
    Lee BS; Nguyen AK; Tekeste TF; Chang K; Girgis A; Adeyemo M; Hanna MS; Yao JF; Kwok KK; Giap AQ; Hunt GC; Chaya CT; Kao KT; Attam R; Ko A; Pio JR; Tovar S; Lim BS
    Pancreatology; 2021 Jan; 21(1):144-154. PubMed ID: 33309223
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Does cyst growth predict malignancy in branch duct intraductal papillary mucinous neoplasms? Results of a large multicenter experience.
    El Chafic A; El Hajj II; DeWitt J; Schmidt CM; Siddiqui A; Sherman S; Aggarwal A; Al-Haddad M
    Dig Liver Dis; 2018 Sep; 50(9):961-968. PubMed ID: 29866630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are the Sendai and Fukuoka consensus guidelines for cystic mucinous neoplasms of the pancreas useful in the initial triage of all suspected pancreatic cystic neoplasms? A single-institution experience with 317 surgically-treated patients.
    Goh BK; Tan DM; Thng CH; Lee SY; Low AS; Chan CY; Wong JS; Lee VT; Cheow PC; Chow PK; Chung AY; Wong WK; Ooi LL
    Ann Surg Oncol; 2014 Jun; 21(6):1919-26. PubMed ID: 24504924
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of high-risk stigmata and worrisome features with advanced neoplasia in intraductal papillary mucinous neoplasms (IPMN): A systematic review.
    Ohno E; Balduzzi A; Hijioka S; De Pastena M; Marchegiani G; Kato H; Takenaka M; Haba S; Salvia R
    Pancreatology; 2024 Feb; 24(1):48-61. PubMed ID: 38161091
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Higher Growth Rate of Branch Duct Intraductal Papillary Mucinous Neoplasms Associates With Worrisome Features.
    Kolb JM; Argiriadi P; Lee K; Liu X; Bagiella E; Gupta S; Lucas AL; Kim MK; Kumta NA; Nagula S; Sarpel U; DiMaio CJ
    Clin Gastroenterol Hepatol; 2018 Sep; 16(9):1481-1487. PubMed ID: 29535058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term follow-up of neoplastic pancreatic cysts without high-risk stigmata: how often do we change treatment strategy because of malignant transformation?
    Lekkerkerker SJ; Besselink MG; Busch OR; Dijk F; Engelbrecht MR; Rauws EA; Fockens P; van Hooft JE
    Scand J Gastroenterol; 2016 Sep; 51(9):1138-43. PubMed ID: 27175891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Natural history of intraductal papillary mucinous neoplasm and non-neoplastic cyst: long-term imaging follow-up study.
    Hisada Y; Nagata N; Imbe K; Takasaki Y; Sekine K; Tajima T; Yanase M; Fujimoto K; Akiyama J; Uemura N
    J Hepatobiliary Pancreat Sci; 2017 Jul; 24(7):401-408. PubMed ID: 28512773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of endoscopic ultrasound-guided ethanol ablation for pancreatic cystic lesions: A single-center experience of 214 patients.
    Choi JH; Lee SH; Choi YH; You MS; Shin BS; Paik WH; Ryu JK; Kim YT
    Hepatobiliary Pancreat Dis Int; 2019 Dec; 18(6):562-568. PubMed ID: 31551143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.